Do you or a loved one suffer from a B-Cell lymphoma which has relapsed, or is no longer responding to standard treatment?

A new, phase 1, first inhuman study has opened this week at LINEAR: TG-1801-101

Patients with relapsed or refractory B-Cell Lymphoma will receive weekly infusions of TG-1801 for the first 2 cycles (2 months) and then monthly infusions, for a total of 6 months maximum treatment.

For more information please visit our “Trials open for recruitment page”  or please contact LINEAR Haematology Clinical Trials:  E – – T: +61 (08) 9386 5125 / 6382 5127